title: Inhibitory effect of resveratrol on angiotensin II-induced cardiomyocyte hypertrophy.
abstract: Resveratrol is proposed to account in part for the protective effect of red wine on the cardiovascular system. Angiotensin II (Ang II) is a potent hypertrophic stimulus in cardiomyocytes. In this study, we determined the effect of resveratrol on Ang II-induced cardiomyocyte hypertrophy. Cultured neonatal rat cardiomyocytes were stimulated with Ang II, and [3H]leucine incorporation and beta-myosin heavy chain (beta-MyHC) promoter activity were examined. Intracellular reactive oxygen species (ROS) were measured by a redox-sensitive fluorescent dye, 2' 7'-dichlorofluorescin diacetate, and the extracellular signal-regulated kinase (ERK) phosphorylation was examined by Western blotting. Resveratrol inhibited Ang II-increased intracellular ROS levels. Furthermore, resveratrol, as well as the antioxidant N-acetyl-cysteine, decreased Ang II- or H2O2-increased protein synthesis, beta-MyHC promoter activity, and ERK phosphorylation. In summary, we demonstrate for the first time that resveratrol inhibits Ang II-induced cardiomyocyte hypertrophy via attenuation of ROS generation.
authors.affiliation: Department of Medicine, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan, Republic of China.
authors.forename: Tzu-Hurng
authors.initials: TH
authors.lastname: Cheng
authors.forename: Ju-Chi
authors.initials: JC
authors.lastname: Liu
authors.forename: Heng
authors.initials: H
authors.lastname: Lin
authors.forename: Neng-Lang
authors.initials: NL
authors.lastname: Shih
authors.forename: Yen-Ling
authors.initials: YL
authors.lastname: Chen
authors.forename: Meng-Ting
authors.initials: MT
authors.lastname: Huang
authors.forename: Paul
authors.initials: P
authors.lastname: Chan
authors.forename: Ching-Feng
authors.initials: CF
authors.lastname: Cheng
authors.forename: Jin-Jer
authors.initials: JJ
authors.lastname: Chen
mesh_terms: D000111:Acetylcysteine / Q000494:pharmacology; D000804:Angiotensin II / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D000975:Antioxidants / Q000494:pharmacology; D002478:Cells, Cultured; D006984:Hypertrophy / Q000517:prevention & control; D007930:Leucine / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D018995:Myosin Heavy Chains / Q000235:genetics; D010766:Phosphorylation; D011401:Promoter Regions, Genetic; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*; D014162:Transfection; D024723:Ventricular Myosins / Q000235:genetics
chemical_list: D000975:Antioxidants; D017382:Reactive Oxygen Species; D013267:Stilbenes; D000804:Angiotensin II; D020928:Mitogen-Activated Protein Kinases; D024723:Ventricular Myosins; D018995:Myosin Heavy Chains; D007930:Leucine; D000077185:Resveratrol; D000111:Acetylcysteine